A small number of cancers (basal cell carcinoma, breast cancer, malignant melanoma, lipoma, squamous cell carcinoma) were reported during the 12-week oral METAOD005 trial
This is today the main research use of AOD-9604 in the metabolic context
The regulatory and supply landscape for retatrutide and semaglutide could not be more different right now, and these practical realities will determine which option is available to most people for the foreseeable future
In the U.S., injectable B12 (cyanocobalamin and hydroxocobalamin) is only available with a prescription, as regulated by the FDA
Patients with Gastrointestinal Disorders People with Crohns disease or celiac disease have trouble absorbing B12
Guidance is provided during consultation